- Poster presentation
- Open Access
Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
Journal of the International AIDS Society volume 13, Article number: P4 (2010)
Purpose of study
Until recently, few prospective data existed to indicate safety/efficacy of NVP with entry CD4 count restricted to <250 (women) or <400 (men) cells/mm3. Two phase IV trials, ARTEN and NEWART, compared virologic safety/efficacy of NVP vs ATV/r on a background of TDF/FTC in HIV+ patients within these CD4 ranges. NEWART (US) was designed to be confirmatory of ARTEN and to supplement ARTEN data .
In NEWART, treatment naïve patients were randomized to open-label NVP 200mg BID (lead-in dose 200mg QD x 14 days) or ATV/r (300/100mg) plus TDF/FTC (300/200mg). Women had CD4 counts (cells/mm3) <250; men <400. Primary endpoint was virologic response prior to and at week 48 defined as confirmed HIV viral load (VL) <50 copies/mL without subsequent rebound or therapy change. A point estimate of -6.5% or higher for difference in proportion of responders (NVP-ATV/r) was considered consistent with a successful ARTEN study.
Summary of results
152 patients were treated: 89% male, 68% White, 31% Black. At baseline, mean log10 VL was 4.9 and median CD4 count (cells/mm3) was 176 (NVP) and 193 (ATV/r). Table 1 summarizes key outcome measures. Mean plasma lipid (mg/dL) changes from baseline through 48 weeks (last observation carried forward) were as follows (NVP and ATV/r arms, respectively): total cholesterol (TC) 18.2 and 13.8 (P=0.73); HDL cholesterol (HDLc) 9.6 and 3.5 (P=0.016); LDL cholesterol (LDLc) 8.7 and 6.9 (P=0.93); and triglycerides -4.7 and 8.4 (P=0.36).
NVP + TDF/FTC was noninferior to ATV/r + TDF/FTC. Although trial discontinuations were greater in the NVP arm, VR was similar because of less documented VF. HDLc increased and TC/HDLc decreased significantly more for NVP than for ATV/r.
Soriano V, Köppe S, Migrone H, et al: International AIDS Society - 5th Conference on HIV Pathogenesis. Treatment & Prevention. 2009
About this article
Cite this article
DeJesus, E., Mills, A., Bhatti, L. et al. Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data. JIAS 13, P4 (2010). https://doi.org/10.1186/1758-2652-13-S4-P4
- Viral Load
- Virologic Response
- Trial Discontinuation